TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22270198

Group type: EXPERIMENTAL
Intervention: A/BPO and DCN followed by A/BPO
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vehicle and DCN followed by A/BPO
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: A/BPO and DCN followed by vehicle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vehicle and DCN followed by vehicle
Number of subjects: 0

Group type: COMPARATOR
Intervention: DCN and vehicle (initial treatment)
Number of subjects: 0
Study: 20004061

Group type: EXPERIMENTAL
Intervention: Amniotic membrane (Biomembrane) dressing
Number of subjects: 46

Group type: COMPARATOR
Intervention: Polyurethane membrane (Tegaderm) dressing
Number of subjects: 46
Study: 17928105

Group type: COMPARATOR
Intervention: Citalopram (20 mg/day) plus placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/day) plus pindolol (7.5 mg/day)
Number of subjects: 0
Study: 15955042

Group type: EXPERIMENTAL
Intervention: Sydenham's chorea (SC) patients
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Rheumatic fever (RF) patients without neurological symptoms
Number of subjects: 220

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 220
Study: 12776276

Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C, 500 mg, three times a week
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 10385721

Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Somatostatin (250 microg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 18
Study: 8721799

Group type: EXPERIMENTAL
Intervention: Volunteer staff performing recruitment tasks (mailings, telephoning, clerical work)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Volunteer staff
Number of subjects: 12
Study: 1513858

Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6148617

Group type: EXPERIMENTAL
Intervention: Intravenous followed by oral propranolol
Number of subjects: 735

Group type: COMPARATOR
Intervention: Control (no propranolol)
Number of subjects: 735
Study: 29452024

Group type: EXPERIMENTAL
Intervention: Expectation of complete recovery
Number of subjects: 252
Study: 29558811

Group type: EXPERIMENTAL
Intervention: Hip-based activity tracking devices
Number of subjects: 32

Group type: COMPARATOR
Intervention: Wrist-based activity tracking devices
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both types of devices
Number of subjects: 32
Study: 26977625

Group type: EXPERIMENTAL
Intervention: Venlafaxine (75-150 mg/day for 4 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Venlafaxine (75-150 mg/day for 4 weeks) plus cerebrolysin (20 i/v infusions during 4 weeks, 20.0 ml in 100 ml isotonic NaCl solution)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (Venlafaxine alone)
Number of subjects: 40
Study: 24284361

Group type: EXPERIMENTAL
Intervention: SNP rs17249141
Number of subjects: 1860

Group type: EXPERIMENTAL
Intervention: SNPs rs2738447, rs14158, rs2738465, rs3180023
Number of subjects: 1860
Study: 22432114

Group type: EXPERIMENTAL
Intervention: Fenofibrate therapy (case subjects, n = 321)
Number of subjects: 1061

Group type: COMPARATOR
Intervention: Fenofibrate control subjects (n = 175)
Number of subjects: 1061

Group type: COMPARATOR
Intervention: Placebo control subjects (n = 565)
Number of subjects: 1061
Study: 19023095

Group type: EXPERIMENTAL
Intervention: TEMPiS intervention (specialized stroke wards, continuous medical education, telemedical consultation)
Number of subjects: 3060

Group type: COMPARATOR
Intervention: Control hospitals (without specialized stroke facilities or telemedical support)
Number of subjects: 3060
Study: 17804936

Group type: EXPERIMENTAL
Intervention: Support group intervention (6 sessions over 2 weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Support group intervention
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 15100508

Group type: EXPERIMENTAL
Intervention: Resting Tl gated SPECT studies
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Redistribution Tl gated SPECT studies
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Visual wall thickening assessment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Automated wall thickening assessment
Number of subjects: 30
Study: 12297844

Group type: EXPERIMENTAL
Intervention: 3 MU IFN alfa‐2b 3 times per week plus ribavirin 1,000 mg/d for 12 months (Group A)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: 5 MU IFN alfa‐2b 3 times per week plus ribavirin for 12 months (Group B)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: 3 MU IFN alfa‐2b 3 times per week plus ribavirin for 6 months (Group C)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: 5 MU IFN alfa‐2b 3 times per week plus ribavirin for 6 months (Group D)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Groups A and B (3 MU and 5 MU for 12 months) in patients with genotype 1 and 4
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Groups A, B, C, D in patients with genotype 2 and 3
Number of subjects: 295
Study: 9613306

Group type: EXPERIMENTAL
Intervention: Mouthpiece
Number of subjects: 52

Group type: COMPARATOR
Intervention: Mask
Number of subjects: 52

Group type: COMPARATOR
Intervention: Mouthpiece with nose clip
Number of subjects: 52
Study: 8134206

Group type: EXPERIMENTAL
Intervention: Indomethacin (0.1 mg/kg intravenously at 6 to 12 postnatal hours and every 24 hours for two more doses)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 431
Study: 2552600

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium, 4 mg four times daily by inhalation
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 1091305

Group type: EXPERIMENTAL
Intervention: Electrosleep (ES) treatment; five half-hour sessions; duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; details not available.
Number of subjects: 0
Study: 31169723

Group type: EXPERIMENTAL
Intervention: Auriculotherapy (A group) with 5 semi-permanent needles inserted in both ears at specific points.
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (C group) with 5 small round patches of adhesive pads positioned bilaterally at the same points.
Number of subjects: 53
Study: 29275795

Group type: EXPERIMENTAL
Intervention: Classical acupuncture with placebo tablet
Number of subjects: 157

Group type: COMPARATOR
Intervention: Sham acupuncture with placebo tablet
Number of subjects: 157

Group type: COMPARATOR
Intervention: Sham acupuncture with ibuprofen
Number of subjects: 157
Study: 25239086

Group type: EXPERIMENTAL
Intervention: Memory rehabilitation intervention
Number of subjects: 24
Study: 23992025

Group type: EXPERIMENTAL
Intervention: Capnography
Number of subjects: 540

Group type: COMPARATOR
Intervention: Control (without capnography)
Number of subjects: 540
Study: 21925346

Group type: EXPERIMENTAL
Intervention: pantethine (600 mg/d for weeks 1-8, then 900 mg/d for weeks 9-16)
Number of subjects: 120

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120
Study: 19905885

Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (Exubera)
Number of subjects: 627

Group type: COMPARATOR
Intervention: Subcutaneous insulin
Number of subjects: 627
Study: 16773951

Group type: EXPERIMENTAL
Intervention: Antidepressants (SSRIs)
Number of subjects: 4487

Group type: EXPERIMENTAL
Intervention: Antidepressants (non-specific)
Number of subjects: 4487

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4487
Study: 12957419

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg/day for four weeks)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 115

Group type: COMPARATOR
Intervention: Aspirin and Placebo
Number of subjects: 115
Study: 11116409

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Open Nissen fundoplication (ONF)
Number of subjects: 42
Study: 8644885

Group type: EXPERIMENTAL
Intervention: Attention allocated to verbal stimulus during addition problems; varying difficulty and instructions.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct test of recognition memory; assessed after addition problems.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indirect test of repetition priming in lexical decision; assessed at lags of 0, 1, or 8 intervening trials.
Number of subjects: 0
Study: 1380989

Group type: EXPERIMENTAL
Intervention: Eflornithine alone
Number of subjects: 98

Group type: COMPARATOR
Intervention: Eflornithine- mitoguazone
Number of subjects: 98
Study: 6150725

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31540876

Group type: EXPERIMENTAL
Intervention: Saba shielding (1 T)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Saba shielding (3 T)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Saba shielding (90% Cu, 10% Bi)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bismuth shielding (100% Bi)
Number of subjects: 20
Study: 31812185

Group type: EXPERIMENTAL
Intervention: Early introduction of allergenic foods
Number of subjects: 0
Study: 28470157

Group type: EXPERIMENTAL
Intervention: Group counseling program based on goal attainment theory (8 sessions, once a week, 45 minutes each)
Number of subjects: 44
Study: 25855628

Group type: EXPERIMENTAL
Intervention: 40 mg prednisone daily for 5 days
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: 40 mg prednisone daily for 14 days
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Prednisone treatment (both 5 and 14 days)
Number of subjects: 311
Study: 22763799

Group type: EXPERIMENTAL
Intervention: Mono-phosphate (MP)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Poly-phosphate (PP)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 21700757

Group type: EXPERIMENTAL
Intervention: CRT-D (Group 1: 26 patients)
Number of subjects: 73

Group type: COMPARATOR
Intervention: CRT-D (Group 2a: 23 patients)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Implantable cardioverter defibrillator (Group 2b: 21 patients)
Number of subjects: 73
Study: 18078906

Group type: EXPERIMENTAL
Intervention: Contrast material containing 300 mg iodine/mL (Iomeprol 300) injected at a rate of 1 g of iodine/second
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Contrast material containing 400 mg iodine/mL (Iomeprol 400) injected at a rate of 1 g of iodine/second
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Including patient body weight in the analysis
Number of subjects: 60
Study: 16610157

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral therapy (n = 26)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Waiting list control condition (n = 29)
Number of subjects: 55
Study: 12826971

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine scalp infiltration
Number of subjects: 41

Group type: COMPARATOR
Intervention: Fentanyl (2 microg/kg intravenous)
Number of subjects: 41
Study: 11596665

Group type: EXPERIMENTAL
Intervention: Perindopril-indapamide combination (ACE inhibitor-diuretic)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Intensive gliclazide MR-based glucose control regimen
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Matching placebo for perindopril-indapamide
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Usual guidelines-based therapy for glucose control
Number of subjects: 10000
Study: 9303949

Group type: EXPERIMENTAL
Intervention: Punishment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Punishment and Control
Number of subjects: 0
Study: 8285750

Group type: EXPERIMENTAL
Intervention: Milk feeds supplemented with Lactobacillus GG 10(8) colony forming units twice a day for two weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Milk feeds
Number of subjects: 20
Study: 3578848

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 0.02% morphine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Saline (30 ml perineurally and 1 ml intramuscularly) with 6 mg morphine
Number of subjects: 25
Study: 30123060

Group type: EXPERIMENTAL
Intervention: Vitamin C and E supplementation (2000 mg/d vitamin C; 1400 U/d vitamin E)
Number of subjects: 18
Study: 27062334

Group type: EXPERIMENTAL
Intervention: Guideline-concordant therapy
Number of subjects: 111

Group type: COMPARATOR
Intervention: Empiric therapy (sulbactam/ampicillin or ceftriaxone)
Number of subjects: 111
Study: 25023798

Group type: EXPERIMENTAL
Intervention: Meloxicam (1 mg/kg of BW) administered orally at loading (d 0), unloading (d 1), and daily from d 2 to 7 of feedlot receiving (MEL)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Lactose monohydrate (1 mg/kg of BW) administered orally (TRANS)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Lactose monohydrate (1 mg/kg of BW) administered orally (CON)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Meloxicam (1 mg/kg of BW) administered orally (MEL)
Number of subjects: 84
Study: 23467862

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injections prior to cast treatment
Number of subjects: 47

Group type: COMPARATOR
Intervention: Below-the-knee casts (control)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both groups (cast treatment and botulinum toxin A)
Number of subjects: 47
Study: 20495802

Group type: EXPERIMENTAL
Intervention: Interference screws (direct form)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Transcondylar cross-pin screw (from a distance)
Number of subjects: 60
Study: 18572334

Group type: EXPERIMENTAL
Intervention: Alendronate 20 mg once weekly
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 16598518

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg bid
Number of subjects: 59

Group type: COMPARATOR
Intervention: Metoprolol 100 mg bid
Number of subjects: 59
Study: 12694145

Group type: EXPERIMENTAL
Intervention: Rectal paracetamol 1000 mg four times daily
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Rectal paracetamol 1000 mg
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Higher paracetamol concentration
Number of subjects: 78
Study: 10894579

Group type: EXPERIMENTAL
Intervention: Digital rectal examination (DRE) in patients with AMI (Group I)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Digital rectal examination (DRE) in patients without AMI (Group III)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control group (Group II) - patients with AMI without DRE
Number of subjects: 480
Study: 9552820

Group type: EXPERIMENTAL
Intervention: Composite inlays
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Composite fillings
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Overall restorations (both inlays and fillings)
Number of subjects: 45
Study: 1590051

Group type: EXPERIMENTAL
Intervention: Cemented fixation (18 knees)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Cementless fixation (15 knees)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Cemented and cementless fixation
Number of subjects: 33
Study: 3812055

Group type: EXPERIMENTAL
Intervention: Physician advice plus nicotine chewing gum (NCG) prescription
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum (NCG) users
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Long-term NCG users (greater than 20 days)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Short-term NCG users
Number of subjects: 289

Group type: COMPARATOR
Intervention: No advice group
Number of subjects: 289
Study: 29669736

Group type: EXPERIMENTAL
Intervention: Tailored letter intervention
Number of subjects: 2014

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2014
Study: 27245219

Group type: EXPERIMENTAL
Intervention: Arthroscopic tennis elbow release (ECRB release)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham lateral portal (no ECRB release)
Number of subjects: 0
Study: 25927224

Group type: COMPARATOR
Intervention: Control
Number of subjects: 982
Study: 22170177

Group type: EXPERIMENTAL
Intervention: Magnesium infusion within 4 days (Group I)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (Group II)
Number of subjects: 30
Study: 16003061

Group type: EXPERIMENTAL
Intervention: Generic and disease-specific HRQOL questionnaires (SF-36 and SGRQ)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Physical Component Score of SF-36
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Mental Component Score of SF-36 and SGRQ scores
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Physical performance measures
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Lung spirometry tests
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Correlation between forced expiratory volume in 1 sec and physical function domain of SF-36
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Correlation between forced expiratory volume in 1 sec and SGRQ domains
Number of subjects: 73
Study: 12011878

Group type: EXPERIMENTAL
Intervention: Paracervical block for labor analgesia
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Paracervical block
Number of subjects: 4
Study: 10732143

Group type: EXPERIMENTAL
Intervention: LH (Luteinizing Hormone)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: FSH (Follicle Stimulating Hormone)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: FSH and LH concentrations
Number of subjects: 6
Study: 7496933

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1,000 mg every 6 h for 2 days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Healthy elderly subjects
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Infirm elderly subjects
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Functional activity score
Number of subjects: 80
Study: 2683263

Group type: EXPERIMENTAL
Intervention: Antilymphocyte globulin (ALG) and prednisone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Cyclosporine (CsA) 10 mg/kg/day and prednisone
Number of subjects: 45
Study: 890617

Group type: EXPERIMENTAL
Intervention: Administration of prophylactic systemic antibiotics in high-risk patients
Number of subjects: 444

Group type: COMPARATOR
Intervention: No specific control intervention mentioned
Number of subjects: 444
Study: 31943807

Group type: EXPERIMENTAL
Intervention: Family-focused therapy (FFT)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Enhanced care (EC)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Treatment as usual (NAPLS2)
Number of subjects: 94
Study: 29962339

Group type: EXPERIMENTAL
Intervention: Thiazide therapy
Number of subjects: 0
Study: 26895652

Group type: EXPERIMENTAL
Intervention: Dynamic light application (DLA) therapy, administered through ceiling-mounted fluorescent tubes delivering bluish-white light up to 1700 lux between 0900 h and 1600 h, except for 1130-1330 h when dimmed to 300 lux.
Number of subjects: 734

Group type: COMPARATOR
Intervention: Normal lighting (control), with light levels at 300 lux and lights could be turned on and off from inside the room.
Number of subjects: 734
Study: 24388379

Group type: EXPERIMENTAL
Intervention: Ketotifen 0.025% ophthalmic solution, one drop twice daily for 28 days
Number of subjects: 75

Group type: COMPARATOR
Intervention: Olopatadine 0.1% ophthalmic solution, one drop twice daily for 28 days
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ketotifen 0.025% ophthalmic solution
Number of subjects: 75
Study: 22704725

Group type: EXPERIMENTAL
Intervention: MenACWY-TT vaccine
Number of subjects: 271
Study: 19800329

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) with stainless steel electrode wires placed alongside the median nerve for immediate 1 h 20 Hz bipolar ES after CTRS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no electrical stimulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both stimulation and control groups
Number of subjects: 0
Study: 18376350

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral glucose load
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Incretin effect calculated using insulin responses
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Incretin effect calculated using C-peptide responses
Number of subjects: 40
Study: 15649722

Group type: EXPERIMENTAL
Intervention: 120 mg acetylsalicylic acid (ASA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 12165118

Group type: EXPERIMENTAL
Intervention: DITPA 1.875 mg/kg daily for 2 weeks, then 3.75 mg/kg daily for 2 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 10442508

Group type: EXPERIMENTAL
Intervention: Ginger rhizome extract (2 x 100 mg)
Number of subjects: 12
Study: 7842149

Group type: EXPERIMENTAL
Intervention: Ultrasound screening at 16 to 22 weeks' gestation and at 31 to 35 weeks' gestation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group received ultrasound screening only for medical indications
Number of subjects: 0
Study: 2171375

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 56

Group type: COMPARATOR
Intervention: Halothane anaesthesia
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia and Halothane anaesthesia
Number of subjects: 56
Study: 580623

Group type: EXPERIMENTAL
Intervention: Propylthiouracil, 150 mg every eight hours
Number of subjects: 49

Group type: COMPARATOR
Intervention: Propylthiouracil, 450 mg as a single daily dose
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Switching to propylthiouracil, 150 mg every eight hours after initial failure
Number of subjects: 49
Study: 31506766

Group type: EXPERIMENTAL
Intervention: Probiotic milk intake during the first half of pregnancy
Number of subjects: 57134
Study: 30614469

Group type: EXPERIMENTAL
Intervention: Ibrutinib plus obinutuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorambucil plus obinutuzumab
Number of subjects: 0
Study: 28913846

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (220 mL daily for 5 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (conventional medical therapies only)
Number of subjects: 100